Danish insulin maker Novo Nordisk said on Thursday it planned to invest 100 million euros in production facilities at its existing 32,000 square metres site in Chartres, France.
Novo Nordisk already employs 1,400 people in France, where a range of the company’s insulin products are produced and exported from.
“With the coming expansion we will further strengthen Chartres’ position in our global product supply organisation,” said Chief Executive Officer, Lars Rebien Sørensen in a statement.
By Nikolaj Skydsgaard
LinkedIn Twitter Xing EmailWhen I left my second large company experience to become President of a small manufacturing company I did so driven by ego; I fancied the title. Soon […]
LinkedIn Twitter Xing EmailFirm details on exactly how the U.K. will regulate new medicines is still to be decided after it leaves the EU later this year (caveats on timing […]
LinkedIn Twitter Xing EmailThe Simply Good Foods Company, the owner of Atkins-branded food products, has secured a deal to acquire protein snack maker Quest Nutrition for $1 billion. Quest, which […]